Log in to search using one of your social media accounts:

 

Cleveland clinic study: Timing of melanoma diagnosis, treatment critical to survival
(Cleveland Clinic) A new Cleveland Clinic study underscores the importance of early detection and treatment of melanoma, the deadliest form of skin cancer. The research, published online today in the Journal of the American Academy of Dermatology, indicates that the sooner patients were treated, the better their survival, particularly for stage I melanoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 17, 2017 Category: Cancer & Oncology Source Type: news

Insurance determines melanoma surgery decision: Study
Surgery is the main treatment for melanoma -- a form of skin cancer -- but insurance may affect whether that cancer is quickly removed, research suggests. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 16, 2017 Category: Consumer Health News Source Type: news

With Skin Cancer Surgery, Insurance Matters
Wait could be more than 6 weeks longer than those with private insurance, study says Source: HealthDay Related MedlinePlus Pages: Health Disparities, Health Insurance, Melanoma (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - October 16, 2017 Category: Consumer Health News Source Type: news

With Skin Cancer Surgery, Insurance Matters
MONDAY, Oct. 16, 2017 -- Surgery is the main treatment for melanoma -- a dangerous form of skin cancer -- but a patient's insurance could affect whether or not that cancer is quickly removed, new research suggests. After reviewing thousands of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 16, 2017 Category: General Medicine Source Type: news

Scientists pinpoint surprising origin of melanoma
(VIB (the Flanders Institute for Biotechnology)) Led by Jean-Christophe Marine (VIB-KU Leuven), a team of researchers has tracked down the cellular origin of cutaneous melanoma, the deadliest form of skin cancer. The team was surprised to observe that these very aggressive tumors arise from mature, pigment-producing cells called melanocytes. As melanoma develops, these cells are eventually reprogrammed, lose their differentiated features and become invasive, migratory cancer cells. This knowledge is vital to understand how these melanoma lesions are formed, facilitate their early detection and develop preventive treatment ...
Source: EurekAlert! - Cancer - October 12, 2017 Category: Cancer & Oncology Source Type: news

Oncolytic Virus Succeeds in Melanoma Trial (CME/CE)
(MedPage Today) -- Add-on to ipilimumab better than drug alone (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - October 10, 2017 Category: Dermatology Source Type: news

Adjuvant Ipilimumab in Melanoma: Future in Doubt Adjuvant Ipilimumab in Melanoma: Future in Doubt
This hugely expensive regimen has now been eclipsed by the checkpoint inhibitor nivolumab, placing the future of adjuvant ipilimumab under question, argues one expert.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 10, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Papers of note in Nature 550 (7674)
This week’s articles highlight retrograde semaphorin signaling at synapses; a driver of age-related decreases in lipolysis; and a mechanism by which melanoma cells become resistant to combined therapies. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - October 10, 2017 Category: Science Authors: VanHook, A. M. Tags: STKE Editors ' Choice Source Type: news

Skin cancer symptoms: Four ways to spot DEADLY melanoma on the scalp
SKIN cancer rates are on the rise, but checking for symptoms on your scalp could help to identify melanoma early, says celebrity hairstylist Edward James. (Source: Daily Express - Health)
Source: Daily Express - Health - October 9, 2017 Category: Consumer Health News Source Type: news

First Randomized Study To Evaluate IMLYGIC ® (Talimogene Laherparepvec), An Oncolytic Viral Therapy, In Combination With A Checkpoint Inhibitor Published In The Journal Of Clinical Oncology
Results Demonstrated a Doubling of Objective Response Rate Compared to Ipilimumab Alone in Unresectable Advanced Melanoma Responses Were Not Limited to Injected Lesions and Favored the Combination Arm Across Subsets of Disease THOUSAND OAKS, Calif., Oct. 5, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology has published positive results from the IMLYGIC® (talimogene laherparepvec) Phase 2 '264 study. The study met its primary endpoint of objective response rate (ORR), demonstrating that IMLYGIC in combination with YERVOY® (ipilimumab) more than doubled ORR, define...
Source: Amgen News Release - October 5, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

This weekend
Americans love to celebrate weekends at the beach or by the pool. If that’s your plan, I hope your day includes a dose of sunshine. However, I have an important message before you cover yourself in sunscreen. Don’t do it! If you’re shaking your head in disbelief, I get it… What I just said goes against everything you’ve heard for the last 40 years or so from doctors, dermatologists and the mainstream media. But I’ve been telling my patients for decades that covering themselves in commercial sunscreen is bad advice.   In fact, since the start of the media campaign to push sunscr...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

Good-guy bacteria may help cancer immunotherapies do their job
(UT Southwestern Medical Center) Individuals with certain types of bacteria in their gut may be more likely to respond well to cancer immunotherapy, researchers at the Harold C. Simmons Comprehensive Cancer Center found in a study of patients with metastatic melanoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 5, 2017 Category: Cancer & Oncology Source Type: news

Propranolol May Delay Progression of Cutaneous Melanoma Propranolol May Delay Progression of Cutaneous Melanoma
Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 4, 2017 Category: Dermatology Tags: Hematology-Oncology News Source Type: news

KC biotech firm develops new drug with promise for fighting multiple cancers
A drug being developed by a Kansas City biotech company shows promise for several types of cancer patients. The targeted therapy, called ulixertinib, has been tested on patients with metastatic melanoma, lung cancer and brain cancer. BioMed Valley Discoveries (BVD), founded with the support of late American Century Investments founder Jim Stowers Jr., recently completed an early-stage clinical trial involving 135 patients with advanced solid tumor cancers. Several patients saw their tumors shrink… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 4, 2017 Category: Pharmaceuticals Authors: Elise Reuter Source Type: news

KC biotech firm develops new drug with promise for fighting multiple cancers
A drug being developed by a Kansas City biotech company shows promise for several types of cancer patients. The targeted therapy, called ulixertinib, has been tested on patients with metastatic melanoma, lung cancer and brain cancer. BioMed Valley Discoveries (BVD), founded with the support of late American Century Investments founder Jim Stowers Jr., recently completed an early-stage clinical trial involving 135 patients with advanced solid tumor cancers. Several patients saw their tumors shrink… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 4, 2017 Category: Biotechnology Authors: Elise Reuter Source Type: news

Insurance Type Linked to Surgery Delay in Melanoma
Surgical treatment delays increased for Medicaid versus private patients, for nonwhite patients (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 4, 2017 Category: Cancer & Oncology Tags: Dermatology, Family Medicine, Internal Medicine, Nursing, Oncology, Pathology, Surgery, Journal, Source Type: news

Is Age a Risk Factor for Lymph Node Positivity in Melanoma? Is Age a Risk Factor for Lymph Node Positivity in Melanoma?
Certain patients with thin melanomas aren't recommended for sentinel lymph node biopsy, but a study suggests that they should be.Medscape Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 4, 2017 Category: Consumer Health News Tags: Dermatology Viewpoint Source Type: news

Need Surgery for Melanoma? Which Insurance Causes Delays? Need Surgery for Melanoma? Which Insurance Causes Delays?
When categorized by insurance type, Medicaid patients had longer delays for melanoma surgery than patients with Medicare and private insurance.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 4, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Delays for melanoma surgeries linked to insurance type
(UNC Lineberger Comprehensive Cancer Center) Researchers report in JAMA Dermatology that surgical treatment delays - defined as surgery that occurred more than six weeks after diagnosis - were common. Medicaid patients were 36 percent more likely than private insurance patients to experience delays. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 4, 2017 Category: Cancer & Oncology Source Type: news

Adjuvant Nivolumab: New Standard of Care for Melanoma? Adjuvant Nivolumab: New Standard of Care for Melanoma?
In resected melanoma, nivolumab improves recurrence-free survival with less toxicity. Dr Jeffrey Weber discusses results of the CheckMate 238 study presented at ESMO 2017Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 29, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Propranolol Use Inversely Linked to Melanoma Recurrence
Patients taking propranolol as off - label adjuvant treatment had reduced risk of recurrence (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 29, 2017 Category: Cancer & Oncology Tags: Dermatology, Internal Medicine, Oncology, Pathology, Pharmacy, Journal, Source Type: news

Researchers look to protect 'self-reactive' immune cells so they can fight melanoma
(UNC Lineberger Comprehensive Cancer Center) UNC Lineberger Comprehensive Cancer Center researchers and colleagues report on a potential new way to fight melanoma by blocking one of the immune system's checks and balances. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 28, 2017 Category: Cancer & Oncology Source Type: news

New insights into melanoma development
(Source: ScienceNOW)
Source: ScienceNOW - September 28, 2017 Category: Science Authors: Shay, J. W. Tags: Genetics, Medicine, Diseases perspective Source Type: news

Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism
TERT promoter mutations (TPMs) are the most common noncoding mutations in cancer. The timing and consequences of TPMs have not been fully established. Here, we show that TPMs acquired at the transition from benign nevus to malignant melanoma do not support telomere maintenance. In vitro experiments revealed that TPMs do not prevent telomere attrition, resulting in cells with critically short and unprotected telomeres. Immortalization by TPMs requires a gradual up-regulation of telomerase, coinciding with telomere fusions. These data suggest that TPMs contribute to tumorigenesis by promoting immortalization and genomic inst...
Source: ScienceNOW - September 28, 2017 Category: Science Authors: Chiba, K., Lorbeer, F. K., Shain, A. H., McSwiggen, D. T., Schruf, E., Oh, A., Ryu, J., Darzacq, X., Bastian, B. C., Hockemeyer, D. Tags: Genetics, Medicine, Diseases reports Source Type: news

Melanoma cells rewire to resist drug treatment, Penn-Wistar team finds
(University of Pennsylvania) A study out this week in Nature, led by scientists from the University of Pennsylvania and The Wistar Institute, reveals why relapses after treatment for metastatic melanoma occur. While combination therapies block off the principal pathway that cancer cells use to fuel their growth, the cells come to bypass this blockade and, like vehicles on a detour route, make use of additional pathways to continue growing and spreading. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 27, 2017 Category: Cancer & Oncology Source Type: news

Papers of note in Nature 549 (7672)
This week’s articles highlight the role of AMPA receptor diffusion in long-term potentiation; a mutation in an embryonic cell lineage that leads to adult neurodegeneration; the structural basis of cGAS activation; a posttranslational modification of the melanocortin-1 receptor that protects against melanoma; and factors from maternal cells that determine whether daughter cells will proliferate. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - September 26, 2017 Category: Science Authors: VanHook, A. M. Tags: STKE Editors ' Choice Source Type: news

Assessing the Cutaneous Side Effects of Melanoma Drugs
(MedPage Today) -- Dermatologists need'hands on'experience (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 24, 2017 Category: Hematology Source Type: news

Skin cancer warning: THIS mark on your nails could be a symptom of deadly condition
SKIN cancer symptoms usually include moles, lumps and ulcers that change in appearance, however a dark stripe - or stripes - running down a nail could be a sign of a particular form of melanoma. (Source: Daily Express - Health)
Source: Daily Express - Health - September 21, 2017 Category: Consumer Health News Source Type: news

Melanoma (Skin Cancer) Quiz: Symptoms & Signs
Title: Melanoma (Skin Cancer) Quiz: Symptoms& SignsCategory: MedicineNet QuizCreated: 6/19/2012 12:00:00 AMLast Editorial Review: 9/20/2017 12:30:16 PM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 20, 2017 Category: Cancer & Oncology Source Type: news

Slowly proliferating melanoma cells with high metastatic properties
(The Wistar Institute) A study conducted at The Wistar Institute has led to the identification of a slowly proliferating and highly invasive melanoma cell subpopulation, characterized by production of a protein associated with invasive behavior. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

Penn researchers identify new target, develop new drug for cancer therapies
(University of Pennsylvania School of Medicine) Opening up a new pathway to fight cancer, researchers at the University of Pennsylvania have found a way to target an enzyme that is crucial to tumor growth while also blocking the mechanism that has made past attempts to target that enzyme resistant to treatment. Researchers were able to use this finding to develop a drug that successfully inhibits tumor growth of melanoma as well as pancreatic and colorectal cancer in mice. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

Tumor-infiltrating B lymphocytes promote melanoma progression & resistance to therapy
(The Wistar Institute) In a multi-institutional collaborative study, scientists at The Wistar Institute and the Medical University of Vienna, Austria, have identified the role of tumor-infiltrating or tumor-associated B-cells ('TABs') in melanoma progression and resistance to targeted therapy. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 19, 2017 Category: Biology Source Type: news

Life- and Eye-Saving New Treatments for Uveal Melanoma Life- and Eye-Saving New Treatments for Uveal Melanoma
Gene testing and immunotherapy have opened the door to treatments that could save the eyesight and the lives of people with uveal melanoma.Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - September 15, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

FDG-PET/CT contributes to anal cancer follow-up
Given its high sensitivity and negative predictive value, French researchers...Read more on AuntMinnie.comRelated Reading: AI algorithm can classify bone lesions on PET/CT images FDG-PET/CT foretells melanoma therapy response New PET tracer could work well for prostate cancer SNMMI: PET/CT with prostate agent changes therapy plans (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 15, 2017 Category: Radiology Source Type: news

Does the Mole Always Come Before the Melanoma? Does the Mole Always Come Before the Melanoma?
Dr Arefa Cassoobhoy highlights one of the week's important news stories for primary care.Medscape Internal Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2017 Category: Consumer Health News Tags: Internal Medicine Commentary Source Type: news

Breakthrough Treatments Arriving for Uveal Melanoma Breakthrough Treatments Arriving for Uveal Melanoma
Gene testing and immunotherapy have opened the door to treatments that could save the eyesight and the lives of people with uveal melanoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 14, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Eye-Saving New Treatment Options for Uveal Melanoma Eye-Saving New Treatment Options for Uveal Melanoma
Gene testing and immunotherapy have opened the door to treatments that could save the eyesight and the lives of people with uveal melanoma.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - September 14, 2017 Category: Pathology Tags: Ophthalmology News Source Type: news

Nivolumab-Ipilimumab Combo for Melanoma: 3-Year Survival Data Nivolumab-Ipilimumab Combo for Melanoma: 3-Year Survival Data
Three-year survival rates with advanced melanoma are 52% with nivolumab and 34% with ipilimumab, but 58% with a sequential combination of the two, according to the latest results comparing the two anticancer biologics separately and together.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Researchers find hint of a link between flu vaccine and miscarriage
Researchers studying the impact of the flu vaccine in pregnancy have found a possible link between miscarriage early in pregnancy in women who received the flu vaccine two years in a row. It’s the first study to identify a potential link between miscarriage and the flu vaccine and the first to assess the effect of repeat influenza […]Related:Melinda Gates decries ‘loss of U.S. leadership’ in global aidFormer CDC chief launches $225 million global health initiativeNew clinical trial might change the standard treatment for melanoma (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - September 13, 2017 Category: Consumer Health News Source Type: news

What to know about a study of flu vaccine and miscarriage
Researchers studying the flu vaccine in pregnancy have found a hint of a possible link between miscarriage early in pregnancy and the flu vaccine in women who received a certain version of the vaccine two years in a row. It’s the first study to identify a potential link between miscarriage and the flu vaccine and the first […]Related:Melinda Gates decries ‘loss of U.S. leadership’ in global aidFormer CDC chief launches $225 million global health initiativeNew clinical trial might change the standard treatment for melanoma (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - September 13, 2017 Category: Consumer Health News Source Type: news

FDG-PET/CT contributes to anal cancer follow-up assessment
Given its high sensitivity and negative predictive value, French researchers...Read more on AuntMinnie.comRelated Reading: AI algorithm can classify bone lesions on PET/CT images FDG-PET/CT foretells melanoma therapy response New PET tracer could work well for prostate cancer SNMMI: PET/CT with prostate agent changes therapy plans (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 13, 2017 Category: Radiology Source Type: news

Wondering if that mole is cancerous? Look at illustrations, not photos
(Brigham Young University) Melanoma kills more than 50,000 people worldwide annually. But because early detection dramatically improves prognoses, a BYU professor is working to help people better identify problematic moles. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 13, 2017 Category: Cancer & Oncology Source Type: news

Dabrafenib, Trametinib Beneficial in Resected Melanoma
Rate of relapse - free survival up for resected stage III melanoma with BRAF V600E, V600K mutations (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 13, 2017 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Conference News, Source Type: news

UCLA starts Phase I stem cell trial for cancers with NY-ESO-1 tumour marker
The University of California, Los Angeles (UCLA) has started a Phase I clinical trial to evaluate new genetically engineered blood-forming stem cells to treat cancers such as melanoma and sarcoma with a specific tumour marker called NY-ESO-1. (Source: Drug Development Technology)
Source: Drug Development Technology - September 12, 2017 Category: Pharmaceuticals Source Type: news

Two Adjuvant Wins for Resected Melanoma (CME/CE)
(MedPage Today) -- Nivolumab, targeted combination slow recurrence in high-risk disease (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - September 12, 2017 Category: General Medicine Source Type: news

Adjuvant Nivolumab Tops Ipilimumab in Melanoma
Longer recurrence - free survival for stage IIIB, IIIC, IV melanoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 12, 2017 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Conference News, Source Type: news

Medical News Today: Advanced melanoma: Groundbreaking trials could transform treatment
An immunotherapy and targeted therapy both promise to bring closer the day when melanoma is a disease that people live with instead of die from. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 12, 2017 Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news

New Adjuvant Option for BRAF Melanoma New Adjuvant Option for BRAF Melanoma
Combined targeting with BRAF and MEK inhibitors will soon move into the adjuvant setting for treating BRAF-V300-positive stage III melanoma, say experts.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Clear Benefit With Adjuvant Nivolumab in Resected Melanoma Clear Benefit With Adjuvant Nivolumab in Resected Melanoma
Adjuvant nivolumab significant improves relapse-free survival and reduces toxicity in comparison with ipilimumab in stage III/IV resected melanoma for patients at risk for relapse, trial results reveal.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Researchers report positive results from two melanoma trials in Australia
Researchers at Melanoma Institute Australia have reported positive results from two clinical trials, COMBI-AD and CheckMate 238, conducted to stop and prevent melanoma progression. (Source: Drug Development Technology)
Source: Drug Development Technology - September 11, 2017 Category: Pharmaceuticals Source Type: news